Improvement of gemfibrozil in life-span increase and spontaneous activity in advanced infant neuronal wax-like lipobrown deposition patients
By using gemfilozi to regulate the signaling pathway, the problem of insufficient treatment methods for neurodegenerative diseases such as cerebral lipofuscin deposition in advanced infantile neurons was solved, and the effect of extending life and improving motor behavior was achieved.
Patent Information
- Application Number
- CN202411249994.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2016-12-29
- Filing Date
- 2017-12-28
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has limited treatment methods for neurodegenerative diseases such as advanced infant neurons such as cereal lipofuscin deposition (LINCL), with supportive or symptomatic treatments, and lacks effective methods to extend patients' lifespan and improve quality of life. .
Gemfibrozil is used as a fibrate drug, and through oral administration, it regulates signaling pathways, reduces neuronal apoptosis, increases anti-inflammatory factors, prolongs lifespan and improves motor behavior.
In the mouse model, it significantly prolonged the lifespan of Cln2(-/-) mice, improved motor behavior, reduced neuronal apoptosis and the load on stored materials in the brain, increased anti-inflammatory factors, proved that gemfilol All have the effects of neuroprotection and lifespan.
Smart Images

Figure CN118903432A_ABST
Abstract
Description
Divisional Application Instructions
[0001] This application is a divisional application of the invention patent application (P1) with the application date of December 28, 2017, the application number of 202210797592.9, and the invention name of "Gemfibrozil increases the lifespan and improves spontaneous activity in patients with late infantile neuronal ceroid lipofuscinosis". The invention patent application (P1) is a divisional application of the invention patent application with the application date of December 28, 2017, the application number of 201780080548.3, and the invention name of "Gemfibrozil increases the lifespan and improves spontaneous activity in patients with late infantile neuronal ceroid lipofuscinosis". Related Applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 440,305, filed December 29, 2016, which is incorporated by reference in its entirety. Technical Field
[0003] The present invention relates to a method for treating a neurodegenerative disease, such as late infantile neuronal ceroid lipofuscinosis. Background Art
[0004] Lysosomes are membrane-enclosed organelles that contain several acid hydrolases responsible for degrading lipids, proteins, carbohydrates, and nucleic acids (De Duve & Wattiaux, 1966). Defects / deficiencies in almost any of these acid hydrolases can lead to accumulation of undigested / partially digested material in lysosomes and form the basis of numerous lysosomal storage diseases (LSDs) (De Duve & Wattiaux, 1966; Perez-Sala et al., 2009). Late infantile neuronal ceroid lipofuscinosis (Jansky-Bielschowsky disease, LINCL, type 2) is a form of NCL, which is caused by excessive mutations of the Cln2 gene. These mutations lead to functional deficiency and / or loss of tripeptidyl peptidase I (TPP-1, a 46kDa, pepsin-insensitive lysosomal protease), leading to accumulation of autofluorescent material in the brain (Sleat et al., 1997; Lane et al., 1996). LINCL usually presents with symptoms at 2 to 4 years of age, and progresses rapidly and leads to death between 8 and 10 years of age due to a significant decrease in the number of neurons and other cells (Lane et al., 1996; Sleat et al., 1997). Therefore, extending the life span and / or improving the quality of life of patients with LINCL or other NCL is an important area of research. However, despite years of investigation, there is only one treatment for this disease (particularly LINCL); all approaches are merely supportive or symptomatic, indicating that new treatments are urgently needed (Chang et al., 2008).
[0005] Several studies have concluded that the induction of neuroinflammatory and apoptotic pathways can be attributed to neuronal damage in most forms of NCL, including LINCL (Geraets et al., 2016; Dhar et al., 2002; Puranam et al., 1997; Kohan et al., 2011). Although inflammation is not an initiating factor in LINCL, a persistent glial-mediated inflammatory response is thought to contribute to disease progression (Cooper et al., 2015; Macauley et al., 2014). Gemfibrozil (gem) is an FDA-approved lipid-lowering drug that is known to reduce circulating triglyceride levels and reduce the risk of hyperlipidemia (Robins et al., 2001; Rubins and Robins, 1992; Rubins et al., 1999). However, recent studies by us and others have shown that in addition to its lipid-lowering effects, gem can also modulate many other signaling pathways responsible for inflammation, T helper cell switching, cell-cell contact, migration, oxidative stress, and lysosomal biogenesis (Ghosh and Pahan, 2012a; Corbett et al., 2012; Ghosh et al., 2012; Jana et al., 2007; Jana and Pahan, 2012; Dasgupta et al., 2007; Pahan et al., 2002; Roy and Pahan, 2009; Ghosh et al., 2015).
[0006] Here, we investigated the therapeutic efficacy of gem in a mouse model of LINCL. (- / -) Behavioral analysis and survival studies in mice showed that gem-treated animals showed extended lifespan and improved locomotor behavior compared to vehicle (0.1% methylcellulose)-treated controls. The load of storage materials and neuronal apoptosis were also partially reduced in gem-treated animals, along with increased levels of phospho-BCL2Associated Agonist Of Cell Death (P-BAD), an anti-apoptotic molecule. In addition, elevated levels of anti-inflammatory factors such as signal transduction inhibitor 3 (SOCS3) and interleukin-1 receptor antagonist (IL-1Ra) were also found in gem-treated animals. In summary, this study showed that gem has an important role in the regulation of Cln2 (- / -) Neuroprotective effects in animals. Summary of the invention
[0007] Provided herein is a method for treating a neurodegenerative disease. The neurodegenerative disease may be neuronal ceroid lipofuscinosis, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, including Parkinson's plus diseases, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or Lewy body dementia (DLB). Batten disease is the most common of a group of diseases called neuronal ceroid lipofuscinosis (NCL). The (NCL) may be infantile NCL (INCL, Santavuori-Haltia disease), late infantile neuronal ceroid lipofuscinosis (LINCL), juvenile NCL (JNCL), or adult NCL. (ANCL). Neurodegenerative diseases may be caused by lysosomal storage diseases. Lysosomal storage diseases can be, for example, Tay-Sach disease, Fabry disease, Niemann-Pick disease, Gaucher disease, Hunter syndrome, alpha-mannosidosis, aspartylglucosaminuria, cholesterol ester storage disease, chronic glucosidase A deficiency, cystinosis, Dallon disease, Farber disease, fucocytic tube disease, or galactosyl sinus disease.
[0008] The method may include administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of a medicament comprising a fibrate. The fibrate may be gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate or clinofibrate.
[0009] Also provided herein is a method of reducing neuronal apoptotic cell death in a subject suffering from a neurodegenerative disease. The method comprises administering to the subject a composition comprising a therapeutically effective amount of an agent that reduces neuronal apoptotic cell death, wherein the agent comprises a fibrate.
[0010] Further provided herein is a method of extending the lifespan of a subject with a neurodegenerative disease. The method comprises administering to the subject a composition comprising a therapeutically effective amount of an agent that extends the lifespan of the subject with the neurodegenerative disease, wherein the agent comprises a fibrate.
[0011] Also provided herein is a method of improving motor behavior in a subject suffering from a neurodegenerative disease. The method comprises administering to the subject a composition comprising a therapeutically effective amount of an agent that improves motor behavior, wherein the agent comprises a fibrate.
[0012] Also provided herein is a method for increasing the level of anti-inflammatory factors in the brain of a subject suffering from late infantile neuronal ceroid lipofuscinosis. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a medicament, which increases the level of anti-inflammatory factors in the brain of a subject suffering from late infantile neuronal ceroid lipofuscinosis relative to a control not receiving the medicament, wherein the medicament comprises a fibrate. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1A-1B :Gemfibrozil (gem) prolongs Cln2 (- / -) The life span of mice was regulated by oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) on Cln2 (- / -) Animals were treated. All groups were treated starting at 4 weeks of age. One group of animals received only MeC as a vehicle. 1A) Kaplan-Meier plots survival rates. 1B) Shows the average number of days of survival for all three groups. 40 mice (n=40) were used per group, including 20 males and 20 females.
[0014] Figures 2A-2F : Gem treatment delayed Cln2 (- / -) Loss of motor activity in mice: Oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) to Cln2 (- / -) Animals (4 weeks old) were treated. After 8 weeks of treatment, the mice were monitored for horizontal activity (2A), movement time (2B), movement frequency (2C), total movement distance (2D), stereotypic behavior counts (2E), and rest time (2F). Cln2 mice that received only the vehicle (- / -) Mice and background-matched wild-type (WT) mice were used as controls. The results represent the mean ± SEM of 12 mice per group (n=12). The proportion of male and female mice in each group was equal.
[0015] Figure 3A-3B : Gem treatment reduced Cln2 (- / -) Storage material in the motor cortex of mice: Cln2 was inhibited by oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC). (- / -) Animals (4 weeks old) were treated. After 8 weeks of treatment, storage pigments were observed in cortical sections by immunofluorescence analysis of subunit C (3A). DAPI was used to visualize cell nuclei. 3B) Subunit C-positive immunofluorescence was quantified in two different sections (two images per section) from each of six different mice per group (n=6) using NIH Image J software as described in the methods section. ap < 0.001 vs. WT control; b p<0.05 for Cln2 (- / -) .
[0016] Figures 4A-4D : Gem treatment reduced Cln2 (- / -) Apoptosis in the motor cortex of mice: Effect of oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) on Cln2 (- / -) Animals (4 weeks old) were treated. After 8 weeks of treatment, cortical sections (directly dorsal to the CA1 hippocampal region) were double labeled for NeuN and TUNEL (4A). NeuN was double labeled for NeuN in two different cortical sections from each of six different mice in each group (n=6). + TUNEL + Cells were counted (4-B). 4C) Motor cortex homogenates were immunoblotted for phosphorylated-BAD. Actin was used as a loading control. 4D) Bands were scanned and values (P-BAD / actin) are expressed relative to WT control. Results represent mean ± SEM of four mice per group.
[0017] Figures 5A-5D : Gem treatment inhibited Cln2 (- / -) Apoptosis in the striatum of mice: Oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) to Cln2 (- / -) Animals (4 weeks old) were treated. After 8 weeks of treatment, striatal sections were double labeled for NeuN and TUNEL (5A). NeuN was detected in two different cortical sections from each of six different mice in each group (n=6) using MicroSuite imaging software on an Olympus IX81 fluorescence microscope. + TUNEL + Cells were counted (5B). 5C) Striatal cortical homogenates were immunoblotted for phosphorylated-BAD. Actin was used as an internal reference for loading. 5D) Bands were scanned and values (P-BAD / actin) are expressed relative to WT control. Results represent mean ± SEM of four mice per group.
[0018] Figures 6A-6F : Gem treatment upregulated Cln2 (- / -) Expression of anti-inflammatory molecules in the CNS of mice: Oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) to Cln2 (- / -)Animals (4 weeks old) were treated. After 8 weeks of treatment, the expression of SOCS3 and IL-1Ra was monitored by Western blotting in motor cortex extracts (6A-6C) and striatal extracts (6D-6F). Actin was used as an internal reference for loading. The bands were scanned and the values (SOCS3 / actin, 6B and 6E; IL-1Ra / actin, 6C and 6F) relative to the WT control cortex (6B and 6C) and striatum (6E and 6F) are presented. The results represent the mean ± SEM of four mice per group.
[0019] Figures 7A-7E : Gem treatment upregulated Cln2 (- / -) Expression of anti-inflammatory molecules in the CNS of mice: Oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) to Cln2 (- / -) Animals (4 weeks old) were treated. After 8 weeks of treatment, striatal sections were double labeled for GFAP and SOCS3 (7A) and Iba1 and SOCS3 (7B). Total SOCS3+ (7C), GFAP+ (7D), and Iba1+ (7E) were detected in two different sections from six different mice per group (n=6) using MicroSuite imaging software on an Olympus IX81 fluorescence microscope. + SOCS3 + (7D) and Iba1 + SOCS3 + (7E) Cells were counted. Results represent the mean ± SEM of four mice per group.
[0020] Figures 8A-8E : Gem treatment upregulated Cln2 (- / -) Expression of IL-1Ra in the striatum of mice: Oral administration of 7.5 mg / kg body weight / day of gem (dissolved in 0.1% MeC) to Cln2 (- / -) Animals (4 weeks old) were treated. After 8 weeks of treatment, striatal sections were double labeled for GFAP and IL-1Ra (8A) and Iba1 and IL-1Ra (8B). Total IL-1Ra was detected in two different sections from six different mice per group (n=6) using MicroSuite imaging software on an Olympus IX81 fluorescence microscope. + (8C), GFAP + IL-1Ra + (8D) and Iba1 + IL-1Ra + (8E) Cells were counted. Results represent the mean ± SEM of four mice per group. DETAILED DESCRIPTION
[0021] The embodiments disclosed below are not intended to be exhaustive or to limit the scope of the disclosure to the precise forms described below, but rather the embodiments are selected and described as examples so that others skilled in the art can utilize the teachings thereof.
[0022] The present disclosure relates to methods of treating neurodegenerative diseases, including neuronal ceroid lipofuscinosis (NCL), particularly late infantile neuronal ceroid lipofuscinosis (LINCL).
[0023] The agent may be a lipid-lowering drug, such as a fibrate. Non-limiting examples of fibrates include gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate and clinofibrate. definition
[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art. In the event of a conflict, this document (including definitions) will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to the methods and materials described herein can be used to practice or test the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods and embodiments disclosed herein are illustrative and non-restrictive only.
[0025] As used herein, the terms "comprise(s)", "include(s)", "having", "has", "may", "containing" and variations thereof are intended to be open transitional phrases, terms or words that do not exclude the possibility of other actions or structures. Unless the context clearly dictates otherwise, the singular forms "a", "an", and "the" include plural references. Whether explicitly stated or not, the present disclosure also encompasses other embodiments that "comprise", "consist of", and "consist essentially of" embodiments or elements provided herein.
[0026] As used herein, "treating," "treat," or "treatment" refers to alleviating the symptoms associated with a condition or disease, or halting the further development or worsening of these symptoms, or avoiding or preventing a disease or disorder. For example, in the context of the present disclosure, successful treatment can include preventing a neurodegenerative disease, alleviating symptoms associated with a neurodegenerative disease, or halting the progression of a disease (e.g., a neurodegenerative disease). As used herein, a control for measuring treatment relative to a control is a subject that has not received a therapeutic agent.
[0027] For the recitation of numerical ranges herein, each intervening number with equal precision is expressly contemplated. For example, for the range 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9; for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are expressly contemplated. Methods for treating neurodegenerative diseases
[0028] Provided herein is a method for treating a neurodegenerative disease. Neurodegenerative diseases can be neuronal ceroid lipofuscinosis, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, including Parkinson's superposition disease, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or Lewy body dementia (DLB) and other diseases. Batten's disease is the most common one in a group of diseases called neuronal ceroid lipofuscinosis (NCL). Neuronal ceroid lipofuscinosis (NCL) can be infantile NCL (INCL), late infantile neuronal ceroid lipofuscinosis (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL). Neurodegenerative diseases may be caused by lysosomal storage diseases. The lysosomal storage disease can be, for example, Tay-Sach disease, Fabry disease, Niemann-Pick disease, Gaucher disease, Hunter syndrome, alpha-mannosidosis, aspartylglucosamiduria, cholesterol ester storage disease, chronic glucosamidase A deficiency, cystinosis, Dallon disease, Farber disease, fucocytic tube disease, or galactose sinus disease.
[0029] NCL is a group of neurodegenerative diseases that include typical autosomal recessive lysosomal storage diseases. NCL may include clinical manifestations such as progressive mental decline, cognitive impairment, visual failure, epileptic seizures, and deterioration of motor function. NCL may be associated with the accumulation of autofluorescent storage materials in neurons and / or other types of cells. NCL can be divided into several types, including types 1 to 10, and the types can be based on the age of onset, ultrastructural variations of accumulated storage materials, and genetic changes. Currently, only one treatment method is available for the treatment of NCL, particularly LINCL. Instead, current treatments only support disease symptoms.
[0030] Many types of NCL may be associated with mutations in the Cln genes. These mutations may be associated with defects or loss of function. For example, late infantile neuronal ceroid lipofuscinosis (LINCL) may be associated with mutations in the gene Cln2, while infantile NCL (INCL) and juvenile NCL (JNCL) may be associated with mutations in the genes Cln1 and Cln3, respectively. Pharmacy
[0031] The agent may be a lipid-lowering drug, such as a fibrate. Non-limiting examples of fibrates include gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate, and clinofibrate. Gemfibrozil (5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid) is commercially available from Pfizer under the trade name Fenofibrate (2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-propionic acid 1-methylethyl ester) is a trademark of Abbvie Other fibrates include clofibrate (2-(4-chlorophenoxy)-2-methyl-propionic acid ethyl ester), bezafibrate (2-(4-(2-(4-chlorobenzoylamino)-ethyl)phenoxy)-2-methyl-propionic acid), ciprofibrate (2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropionic acid), and clinofibrate (2-[4-[1-[4-(2-carboxybutyl-2-oxy)phenyl]cyclohexyl]phenoxy]-2-methylbutanoic acid). Pharmaceutical composition
[0032] The agent can be incorporated into a pharmaceutical composition suitable for administration to a subject (eg, a patient, which can be human or non-human).
[0033] A pharmaceutical composition may include a "therapeutically effective amount" or a "prophylactically effective amount" of a medicament. A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the dosage and time period necessary. The therapeutically effective amount of a composition can be determined by one skilled in the art and may vary depending on factors such as the disease state, age, sex, and weight of the individual, as well as the ability of the composition to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which the beneficial effects of the treatment outweigh any toxic or deleterious effects of the medicament. A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic outcome at the dosage and time period necessary. Typically, since a prophylactic dose is used in a subject before or at an early stage of the disease, the prophylactically effective amount will be less than the therapeutically effective amount.
[0034] For example, a therapeutically effective amount of gemfibrozil can be from about 5 mg to about 2000 mg, from about 10 mg to about 1900 mg, from about 15 mg to about 1800 mg, from about 20 mg to about 1700 mg, from about 25 mg to about 1600 mg, from about 30 mg to about 1500 mg, from about 35 mg to about 1400 mg, from about 40 mg to about 1300 mg, from about 45 mg to about 1200 mg, from about 50 mg to about 1100 mg, from about 55 mg to about 1000 mg, from about 60 mg to about 900 mg, from about 65 mg to about 800 mg, from about 70 mg to about 700 mg, from about 75 mg to about 600 mg, from about 80 mg to about 500 mg, from about 85 mg to about 400 mg, from about 90 mg to about 300 mg, from about 95 mg to about 200 mg, or from about 100 mg to about 175 mg. In another example, the therapeutically effective amount of gemfibrozil can be about 600 mg or about 1200 mg.
[0035] For example, a therapeutically effective amount of fenofibrate can be from about 5 mg to about 2000 mg, from about 10 mg to about 1900 mg, from about 15 mg to about 1800 mg, from about 20 mg to about 1700 mg, from about 25 mg to about 1600 mg, from about 30 mg to about 1500 mg, from about 35 mg to about 1400 mg, from about 40 mg to about 1300 mg, from about 45 mg to about 1200 mg, from about 50 mg to about 1100 mg, from about 55 mg to about 1000 mg, from about 60 mg to about 900 mg, from about 65 mg to about 800 mg, from about 70 mg to about 700 mg, from about 75 mg to about 600 mg, from about 80 mg to about 500 mg, from about 85 mg to about 400 mg, from about 90 mg to about 300 mg, from about 95 mg to about 200 mg, or from about 100 mg to about 175 mg. In another example, the therapeutically effective amount of fenofibrate can be about 40 mg, about 48 mg, about 54 mg, about 67 mg, about 100 mg, about 120 mg, about 134 mg, about 145 mg, about 160 mg, or about 200 mg.
[0036] For example, the therapeutically effective amount of clofibrate can be about 5 mg to about 2000 mg, about 10 mg to about 1900 mg, about 15 mg to about 1800 mg, about 20 mg to about 1700 mg, about 25 mg to about 1600 mg, about 30 mg to about 1500 mg, about 35 mg to about 1400 mg, about 40 mg to about 1300 mg, about 45 mg to about 1200 mg, about 50 mg to about 1100 mg, about 55 mg to about 1000 mg, about 60 mg to about 900 mg, about 65 mg to about 800 mg, about 70 mg to about 700 mg, about 75 mg to about 600 mg, about 80 mg to about 500 mg, about 85 mg to about 400 mg, about 90 mg to about 300 mg, about 95 mg to about 200 mg, or about 100 mg to about 175 mg. In another example, the therapeutically effective amount of clofibrate can be about 500 mg.
[0037] The pharmaceutical composition may include a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" as used herein refers to a non-toxic, inert solid, semisolid or liquid filler, diluent, encapsulating material or any type of formulation aid. Some examples of materials that can be used as pharmaceutically acceptable carriers are sugars, such as but not limited to lactose, glucose and sucrose; starches, such as but not limited to corn starch and potato starch; cellulose and its derivatives, such as but not limited to sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered yarrow; malt; gelatin; talc; excipients, such as but not limited to cocoa butter and suppository wax; oils, such as but not limited to peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such as propylene glycol; esters, such as but not limited to ethyl oleate and ethyl laurate; agar; buffers, such as but not limited to magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution (Ringer's solution); ethanol, phosphate buffered solution, and other nontoxic compatible lubricants, such as but not limited to sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweeteners, flavoring agents and fragrances; preservatives and antioxidants may also be present in the composition at the discretion of the formulator. Dosage
[0038] Methods for treating neurological diseases (e.g., late infantile neuronal ceroid lipofuscinosis) may include any number of modes of administering a medicament or a pharmaceutical composition. The modes of administration may include tablets, pills, dragees, hard and soft gel capsules, granules, pills, aqueous solutions, lipids, oily or other solutions, emulsions such as oil-in-water emulsions, liposomes, aqueous or oily suspensions, syrups, elixirs, solid emulsions, solid dispersions, or dispersible powders. To prepare a pharmaceutical composition for oral administration, the medicament may be mixed with commonly known and used adjuvants and excipients, such as gum arabic, talc, starch, sugars (e.g., mannose, methylcellulose, lactose), gelatin, surfactants, magnesium stearate, aqueous or non-aqueous solvents, paraffin derivatives, crosslinking agents, dispersants, emulsifiers, lubricants, preservatives, flavoring agents (e.g., ethereal oils), solubility enhancers (e.g., benzyl benzoate or benzyl alcohol), or bioavailability enhancers (e.g., Gelucire™). In the pharmaceutical composition, the agent may also be dispersed in a particulate composition, such as a nanoparticulate composition.
[0039] For parenteral administration, the medicament or the pharmaceutical composition of the medicament can be dissolved or suspended in a physiologically acceptable diluent, such as water, a buffer, an oil with or without a solubilizing agent, a surfactant, a dispersant or an emulsifier. As oil, for example, but not limited to olive oil, peanut oil, cottonseed oil, soybean oil, castor oil and sesame oil can be used. More generally, for parenteral administration, the medicament or the pharmaceutical composition of the medicament can be in the form of a solution or suspension of an aqueous, lipid, oily or other type, or even administered in the form of a liposome or nanosuspension.
[0040] The term "oral" as used herein refers to administration routes including oral, enteral, buccal, sublabial, sublingual, gastric and rectal administration.
[0041] The term "parenteral" as used herein refers to modes of administration including intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
[0042] The present disclosure has several aspects, illustrated by the following non-limiting examples. Example
[0043] Example 1: Materials and methods:
[0044] Reagents and antibodies: Reagents for TUNEL assays on frozen brain sections were purchased from EMD Millipore (Billerica, MA), and experiments were performed according to the manufacturer's instructions. Blocking buffer and secondary antibodies (IRDye 700 or IRDye 800 labeled) for immunoblotting (IB) were purchased from Licor (Lincoln, NE). Secondary antibodies (FITC or Cy5-labeled) for immunohistochemistry (IHC) were purchased from Jackson ImmunoResearch (West Grove, PA). The sources of the primary antibodies used in this study and their applications and dilutions are listed in Table 1.
[0045] Animals: Animal maintenance and experiments were in accordance with the National Institutes of Health and approved by the Institutional Animal Care and Use Committee (IACUC) of Rush University Medical Center, Chicago, IL. Animals showing mild seizures and tremors were fed and given water by animal feeding. However, if any mouse entered the moribund stage, it was decapitated after anesthesia with ketamine / xylazine injection. Moribund conditions were as follows: central nervous system disturbances (head tilt, seizures, tremors, circling, spasms, and paralysis); inability to remain upright; signs of muscle atrophy; chronic diarrhea or constipation; rough coat and distended abdomen; spread of areas of hair loss caused by the disease; cough, rales, wheezing, and nasal discharge; marked jaundice and / or pallor (anemia); marked discolored urine, polyuria, or anuria; frank bleeding from any orifice / mouth; persistent self-induced trauma. Cln2 (+ / -) Animals were provided by Dr. Peter Lobel (Center for Advanced Biotechnology and Medicine, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA). These animals were inbred and subsequent generations were screened by RTPCR to obtain further Cln2 (+ / +) 、Cln2 (+ / -) and Cln2 (- / -) These Cln2 (- / -) The animals have undetectable TPP1 activity and mimic similar features of the human disease, including reduced motor behavior, reduced lifespan, increased neuropathology in the CNS, and enhanced glial activation (Sleat et al. 2004).
[0046] Treating Cln2 with Gemfibrozil (GEM) (- / -)Mice: Cln2 from the same background, age- and sex-matched (+ / +) Mice were used as wild-type (WT) controls, and Cln2 (- / -) Animals were used for different treatment groups. Gem (7.5 mg / kg body weight / day) was dissolved in DMSO and then diluted in 0.1% methylcellulose (MeC). Cln2 (- / -) Mice were not fed (untreated group), gavaged with 0.1% MeC (vehicle treated group), or gavaged with gem (gem treated group) for 8 weeks for biochemical studies. Similar treatment protocols were followed as long as the animals were not considered morbid as described above for survival studies. Here, 40 mice (20 males and 20 females) were used per group, and animals (4 weeks old) in any group were randomly selected.
[0047] Locomotor activity: Locomotor activity was measured in Cln2 cells after 8 weeks of gem treatment using a Digiscan monitor (Omnitech Electronics Inc., Columbus, OH) as described by us (Khasnavis & Pahan 2014; Ghosh et al., 2007; Ghosh et al., 2009). (- / -) Spontaneous activity was measured in mice. The Digiscan detector records basic spontaneous activity parameters, such as horizontal activity, total distance traveled, movement time, rest time, etc., as well as stereotypic behaviors directly controlled by the striatum. Briefly, mice were taken directly from their cages and first gently placed their noses into a designated corner of an open-field apparatus; after release, data acquisition was started every 5 minutes. Horizontal and vertical activity data, which were automatically monitored by infrared beams, were analyzed and stored using the DIGISCAN software. Here, 12 animals were used in each group. After the open-field test, six of these mice (n=6) were perfused for immunohistochemical analysis, and 4 mice (n=4) were used for Western blot analysis.
[0048] Immunohistochemistry and cell counting: After 8 weeks of treatment, mice were sacrificed and their brains were fixed, embedded, and processed. Sections (30 μm) were prepared from different brain regions (motor cortex and striatum) using a Leica Cryostat, and immunofluorescence staining of fresh frozen sections was performed as described (Corbett et al., 2015; Roy et al., 2015; Roy et al., 2016). Briefly, sections were incubated in 100 mM glycine for 20 min to reduce autofluorescence before adding blocking buffer (2% BSA in PBS). Detailed information on antibody concentrations can be found in Table 1. Samples were mounted and observed under an Olympus IX41 fluorescence microscope. Counting analysis was performed using Olympus Microsuite V software with the help of the touch counting module (Corbett et al., 2015; Roy et al., 2015). After acquiring images under a 20X objective, the images were further analyzed as described below. Before counting cells, the entire image area was calibrated with the help of a rectangular box in the touch counting panel. Once the area of the image has been measured, the touch count program is applied to count the number of fluorescent signals using a simple mouse click method. Next, the total number of signals in a given area is divided by the total area of the image and expressed as the number of cells per square millimeter.
[0049] Detection of storage material: The subunit c of mitochondrial ATP synthase (SCMAS) was monitored by immunofluorescence. For details on antibody dilution, see Table 1. DAPI was used to monitor the nuclei. SCMAS-related fluorescence intensity was quantified by using Olympus Microsuite V software. Briefly, the captured images were opened in the infinity image viewer and contours were drawn around the particles to obtain the fluorescence intensity.
[0050] Immunoblot analysis: After 8 weeks of treatment, mice were killed and the cortical and striatal regions were isolated and homogenized in RIPA buffer (150 mM sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulfate), 50 mM Tris, pH 8.0). The supernatant was taken and the protein was estimated by BioRad protein assay. Equal amounts of protein from tissue extracts were separated in 12% or 15% Bis-Tris gels and transferred to nitrocellulose membranes (Bio-Rad) using Thermo-Pierce FastSemi-Dry Blotter (Corbett et al., 2015; Roy et al., 2015; Roy et al., 2016). The membrane was then washed in TBS plus Tween 20 (TBST) for 15 minutes and blocked in TBST containing BSA for 1 hour. Next, the membranes were incubated overnight at 4°C with shaking with antibodies to the following proteins: β-actin, IL-1Ra, phospho-BAD, and SOCS3. See Table 1 for details on antibody dilutions. The next day, the membranes were washed in TBST for 1 h, incubated in secondary antibodies against the primary antibody host (all 1:10,000; Jackson ImmunoResearch) for 1 h, washed again for 1 h, and Imaging was performed using an infrared imaging system (Li-COR, Lincoln, NE).
[0051] Statistical analysis: All values are expressed as mean ± SEM. One-way ANOVA followed by Tukey or Scheffé post hoc test was performed using SPSS19, and Student's t test and Kaplan-Meier survival estimator (χ 2 ) for data analysis.
[0052] Example 2: Gem treatment prolongs Cln2 (- / -) Lifespan of mice: Cln2 (- / -) Mice are an important animal model for testing new therapeutic approaches against LINCL (Cabrera-Salazar et al., 2007; Sleat et al., 2008; Chang et al., 2008; Sleat et al., 2004). Typically, LINCL progresses rapidly, ending with death between 8 and 10 years of age (Sohar et al., 1999; Sleat et al., 1997). Similarly, Cln2 (- / -) Mice also die within 140 days (Sleat et al., 2004). Therefore, we first examined whether oral gem treatment could increase Cln2 (- / -)The life span of mice. Earlier we have shown that gem enters the CNS after oral administration (Dasgupta et al., 2007). Starting from 4 weeks of age, mice were treated with gem daily by gavage (7.5 mg / kg body weight / day). Since gem was dissolved in 0.1% methylcellulose, a group of Cln2 (- / -) Mice also received 0.1% methylcellulose as vehicle. (- / -) Male and female mice began to die from day 95, and within 137 days, all Cln2 (- / -) Mouse death ( Figure 1A ). In terms of survival, we did not find any significant differences between male and female Cln2 (- / -) However, the Cln2 (- / -) The mice survived to 204 days, indicating that gem can activate Cln2 (- / -) The life span of mice was extended by more than 2 months ( Figure 1A On the other hand, all vehicle-treated mice died within 150 days ( Figure 1A ), indicating that the protection provided by the vehicle alone was very modest. These results were also supported by the average survival days of mice in each group ( Figure 1B ).
[0053] Example 3: Gem treatment improves Cln2 (- / -) Motor behavior in mice: In addition to increasing lifespan, another therapeutic goal for neuroprotection in LINCL patients is to reduce functional impairment. Therefore, to examine whether gem not only increases lifespan but also improves Cln2 (- / -) We monitored the locomotor activity of mice 8 weeks after GEM treatment. Compared with WT mice, Cln2 (- / -) Horizontal activity of mice ( Figure 2A )、Exercise time( Figure 2B )、Number of exercises( Figure 2C ), the total distance traveled( Figure 2D ) and stereotyped behavior counts ( Figure 2E ) was significantly reduced. On the other hand, Cln2 (- / -) The rest time of mice was more than that of WT mice ( Figure 2F ). However, oral administration of gem significantly improved Cln2 (- / -) The motor activity of mice ( Figure 2A -F).
[0054] Example 4: Gem treatment reduces Cln2 (- / -)Storage material burden in mouse brain: A common feature of lysosomal storage diseases, including LINCL, is the accumulation of autofluorescent inclusion bodies in all tissues, including the brain (Boustany 2013; Hachiya et al., 2006). We recently described that gemfibrozil can stimulate lysosomal biogenesis through PPARα-mediated upregulation of TFEB transcription (Ghosh et al., 2015). Since gem treatment extended lifespan and improved Cln2 (- / -) To investigate the motor behavior of mice, we examined whether GEM treatment could reduce the load of endogenous storage material in the motor cortex. As expected, we observed that Cln2 (- / -) The accumulation of subunit c of mitochondrial ATP synthase (SCMAS) was significantly increased in the motor cortex of mice ( Figure 3A -B). However, Cln2 (- / -) GEM treatment of mice resulted in a significant decrease in SCMAS ( Figure 3A -B). These results are specific, as vehicle treatment did not result in such a reduction in storage material ( Figure 3A -B).
[0055] Example 5: Gem treatment to avoid Cln2 (- / -) Neuronal apoptosis in mouse brain: As seen in other neurodegenerative diseases (Cotman and Anderson 1995, Saha and Pahan 2006), apoptosis is also responsible for neuronal degeneration in LINCL (Dhar et al., 2002; Puranam et al., 1997; Lane et al., 1996). Therefore, we examined whether gem treatment could inhibit Cln2 (- / -) Neuronal apoptosis in the CNS of mice. Figure 4A -B clearly shows that NeuN-positive neurons are in Cln2 (- / -) The mice underwent apoptosis in the motor cortex.
[0056] However, oral treatment with gem strongly inhibited neuronal apoptosis in the motor cortex in vivo ( Figure 4A -B). These results are specific, as vehicle (0.1% methylcellulose) treatment did not inhibit neuronal apoptosis ( Figure 4A -B). Although BAD is an apoptotic molecule, phosphorylation of BAD is known to support cell survival (Datta et al., 1999; Datta et al., 2002). Therefore, we examined the role of Cln2 (- / -) Phosphorylated BAD (P-BAD) levels in the motor cortex of mice. Consistent with increased apoptosis, P-BAD levels were increased in Cln2 (- / -)The motor cortex of mice decreased ( Figure 4C -D). However, treatment of Cln2 with gem rather than vehicle (- / -) mice resulting in upregulation of P-BAD ( Figure 4C To understand whether the effects of gem were limited to the motor cortex or whether other parts of the brain also benefited from gem treatment, we monitored apoptosis in the striatum. Similar to the motor cortex, we also observed that Cln2 (- / -) Increased apoptosis in the striatum of mice ( Figure 5A -B) and P-BAD reduction ( Figure 5C -D). However, gem treatment reduced neuronal apoptosis in the striatum in vivo ( Figure 5A -B), and increased levels of P-BAD ( Figure 5C -D), indicating that oral gem treatment can inhibit Cln2 (- / -) Apoptosis in different parts of the mouse brain.
[0057] Example 6: Gem increases Cln2 (- / -) Levels of anti-inflammatory factors in mouse brain: We have shown that gem has anti-inflammatory effects (Jana and Pahan, 2012; Jana et al., 2007; Pahan et al., 2002), and gem increases the levels of SOCS3 and IL-1Ra anti-inflammatory factors in different brain cells (Corbett et al., 2012; Ghosh and Pahan, 2012b). Therefore, here, we investigated whether gem treatment could increase the expression of anti-inflammatory factors in Cln2 (- / -) At 12 weeks of age, we observed that Cln2 (- / -) The motor cortex of mice ( Fig. 6A -C) and striatum ( Fig.6D -F) decreased SOCS3 and IL-1Ra. However, after 8 weeks of oral treatment with gem but not vehicle, there was a significant decrease in SOCS3 and IL-1Ra in Cln2 (- / -) SOCS3 was shown in the motor cortex and striatum of mice. Fig. 6A , B, D and E) and IL-1Ra ( Fig. 6A To further confirm these findings, we next performed double-label immunofluorescence in striatal sections. Although we observed an increase in Cln2 compared with WT mice (- / -) The mice had more astrocytes in their striatal slices ( Fig. 7A ) and microglia ( Figure 7B ), but compared with the latter, the former had a reduced SOCS3 ( Fig. 7A-C). However, similar to the Western blot results, after GEM treatment, (- / -) A significant increase in SOCS3 was observed in the striatum of mice ( Fig. 7A -C). This increase in SOCS3 is found in astrocytes ( Fig. 7A and D), microglia ( Figure 7B Similar to SOCS3, we also noticed that Cln2 (- / -) Loss of IL-1Ra in the striatum of mice Fig. 8A -E). However, treatment of Cln2 with gem rather than vehicle (- / -) mice resulting in restoration and / or upregulation of IL-1Ra in the striatum ( Fig. 8A -E). Similarly, gem-induced Cln2 (- / -) Increased IL-1Ra in the striatum of mice is present in astrocytes ( Fig. 8A and D) and microglia ( Figure 8B and E). Interestingly, in Cln2 (- / -) In the motor cortex and striatum of mice, we did not observe any reduction in astrocytes or microglia after gem treatment (Figures 7 and 8), suggesting that once Cln2 (- / -) Astrogliosis and microgliosis occur in the brains of mice with chronic neurodegenerative diseases, gemfibrozil treatment may simply modulate their function to an anti-inflammatory mode without reducing their number.
[0058] Discussion of Examples 2-6
[0059] Mutations in Cln2 result in deficiency and / or loss of function of the TPP1 enzyme, ultimately leading to LINCL (Bellettato and Scarpa, 2010; Walus et al., 2010; Sohar et al., 1999). Although clinical trials of enzyme replacement therapy and gene therapy are ongoing, there are currently no established drug-mediated therapies for LINCL. Therefore, the development of neuroprotective treatments to delay disease progression, improve motor function, and increase survival in patients with LINCL is critical. Cln2 (- / -) Mice can be used to identify new therapeutic strategies and test the efficacy of new drugs against LINCL. Here, we show for the first time that gemfibrozil (gem), an FDA-approved drug for hyperlipidemia in humans, can improve motor function and prolong Cln2 (- / -) We have recently described that gemfibrozil is able to upregulate TPP1 in cultured mouse and human brain cells and in the mouse brain in vivo via the PPARα / RXRα pathway (Ghosh et al., 2012).(- / -) TPP1 is absent in mice. Therefore, in this case, GEM employs a TPP1-independent mechanism to delay Cln2 (- / -) Disease progression in mice.
[0060] Although the importance of autofluorescent storage material in the pathogenesis of LSDs, including LINCL, remains unclear, these inclusions are one of the hallmarks of LSDs (Boustany 2013). We have recently demonstrated that gem can stimulate lysosomal biogenesis through PPARα-mediated TFEB transcriptional activation (Ghosh et al., 2015), suggesting that storage material can be reduced by gem treatment. Thus, gem can reduce the production of Cln2 (- / -) storage material in the motor cortex of mice. Thus, even in the absence of TPP1, an important enzyme in the degradation pathway, gem could stimulate autophagic clearance through TFEB-mediated activation of other lysosomal enzymes. Earlier we have shown that in skin fibroblasts from patients with LINCL, the combination of gemfibrozil and retinoic acid leads to an increase in lysosomal biogenesis, independent of the disease state (Ghosh et al., 2015).
[0061] Neuronal apoptosis is a hallmark of most known neurodegenerative diseases, including lysosomal storage diseases (Dhar et al., 2002; Puranam et al., 1997; Lane et al., 1996). (- / -) The strong inhibition of neuronal apoptosis in different parts of the CNS of mice suggests that this anti-apoptotic property of gem may contribute to its lifespan-extending efficacy in these mice. BAD, a member of the BCL-2 family, is an important regulator of apoptosis (Datta et al., 1999; Datta et al., 2002). The non-phosphorylated form of BAD is known to induce apoptosis by forming heterodimers with the survival proteins Bcl-x and Bcl-2, allowing the aggregation of two other pro-apoptotic proteins BAK and BAX and inducing the release of cytochrome c (Datta et al., 1999; Datta et al., 2002). On the other hand, phosphorylated BAD is sequestered in the cytoplasm by binding to 14-3-3, allowing cell survival. Here, we have demonstrated that gem treatment restores / upregulates Cln2 (- / -)P-BAD levels in the motor cortex and striatum of mice. The signal transduction mechanism leading to the phosphorylation of BAD has become clear. Phosphatidylinositol-3 kinase (PI3K) is a key signaling molecule involved in the regulation of a wide range of biological responses including cell survival (Koyasu 2003). Some studies have shown that activation of PI3K leads to phosphorylation of BAD through Akt (Ellert-Miklaszewska et al., 2005; Li et al., 2001). Interestingly, gem induces activation of p85α-related IA PI3K in brain cells (Jana et al., 2007). Therefore, gem may inhibit Cln2 through the PI3K-(P)BAD pathway. (- / -) Apoptosis in the mouse CNS.
[0062] Although there are many causes of apoptosis in the CNS, neuroinflammation is an important cause. Therefore, chronic inflammation mediated by activated glial cells is becoming a hallmark of several neurodegenerative diseases, including LINCL (Shyng and Sands 2014; Cooper et al., 2015; Macauley et al., 2014). IL-1β is a proinflammatory cytokine that is involved in the pathogenesis of neurodegenerative diseases. Although IL-1β binds to its high-affinity receptor IL-1R and upregulates proinflammatory signaling pathways, IL-1R antagonists (IL-1Ra) adhere to the same receptor and inhibit proinflammatory cell signaling (Basu et al., 2004). Similarly, inhibitors of cytokine signaling (SOCS) proteins also play a crucial role in inhibiting cytokine signaling and inflammatory gene expression in various cell types, including glial cells (Baker et al., 2009; Chen et al., 2000). Therefore, upregulation of IL-1Ra and SOCS is considered important in reducing inflammation. Recently, we have shown that gem upregulates SOCS3 in glial cells through PI3K-mediated KLF4 activation (Ghosh and Pahan, 2012b), and gem increases IL-1Ra through PI3K-mediated CREB activation (Corbett et al., 2012). It is important to see that gem treatment increases Cln2 (- / -) Thus, by upregulating these important anti-inflammatory molecules, gem could protect and delay Cln2 (- / -) Disease onset in mice.
[0063] Compared with other expected neuroprotective agents, gem has several advantages. For example, gem is an oral drug and is quite non-toxic (Backes et al., 2007; Roy and Pahan, 2009; Pahan, 2006). It has been well tolerated in human and animal studies. Since its approval by the FDA in 1981, it has been called "Lopid" in pharmacies and is a commonly used lipid-lowering drug for humans. The Veterans Administration High-density Lipoprotein Cholesterol Intervention Study (VA-HIT) reported that when the main lipid abnormality in patients was low HDL-C, gem significantly reduced coronary heart disease events (event) (Robins et al., 2001). In a double-blind, randomized, placebo-controlled trial, the drug reduced small low-density lipoprotein (small low-density lipoprotein) more in normolipidemic subjects classified as low-density lipoprotein pattern B than in pattern A (Superko et al., 2005). Another recent trial showed that LDL and HDL particle subclasses were favorably altered by gem therapy (Otvos et al., 2006). Gem can also lower triglycerides and raise HDL with reasonable safety in a pediatric population with metabolic syndrome (Smalley and Goldberg, 2008).
[0064] In conclusion, we have demonstrated that gemfibrozil, an FDA-approved lipid-lowering drug in humans, can reduce storage material, upregulate anti-inflammatory molecules, inhibit neuronal apoptosis, and prolong Cln2 (- / -) Although Cln2 (- / -) The in vivo conditions in the mouse brain and its treatment with gem may not truly resemble the in vivo neurodegenerative conditions in LINCL patients, but our results identify gem as a possible therapeutic agent to extend the lifespan of LINCL patients.
[0065] The above drawings and disclosure are intended to be illustrative and not exhaustive. This specification provides many variations and alternatives to those of ordinary skill in the art. All of these variations and alternatives are intended to be included within the scope of the appended claims. Those skilled in the art may recognize other equivalent implementations of the specific embodiments described herein, and these equivalent implementations are also intended to be covered by the appended claims.
[0066] Table 1: Antibodies used, sources, applications and diluents WB: Western blot; IHC: immunohistochemistry; GFAP: glial fibrillary acidic protein; SOCS3: suppressor of cytokine signaling 3; IL-1Ra: interleukin-1 receptor antagonist. References Backes, J.M., Gibson, C.A., Ruisinger, J.F., and Moriarty, P.M. (2007). Fibrates: what have we learned in the past 40 years? Pharmacotherapy, 27, 412 - 424. Baker, B.J., Akhtar, L.N., and Benveniste, E.N. (2009). SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol, 30, 392 - 400. Basu, A., Krady, J.K., and Levison, S.W. (2004). Interleukin - 1: a master regulator of neuroinflammation. J Neurosci Res, 78, 151 - 156. Bellettato, C.M., and Scarpa, M. (2010). Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis, 33, 347 - 362. Boustany, R.M. (2013). Lysosomal storage diseases - the horizon expands. Nat Rev Neurol, 9, 583 - 598. Cabrera - Salazar, M.A., Roskelley, E.M., Bu, J., et al. (2007). Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. Mol Ther, 15, 1782 - 1788. Chang, M., Cooper, J. D., Sleat, D. E., Cheng, S. H., Dodge, J. C., Passini, M. A., Lobel, P., and Davidson, B. L. (2008). Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther, 16, 649 - 656. Chen, X. P., Losman, J. A., and Rothman, P. (2000). SOCS proteins, regulators of intracellular signaling. Immunity, 13, 287 - 290. Cooper, J. D., Tarczyluk, M. A., and Nelvagal, H. R. (2015). Towards a new understanding of NCL pathogenesis. Biochim Biophys Acta, 1852, 2256 - 2261. Corbett, G. T., Gonzalez, F. J., and Pahan, K. (2015). Activation of peroxisome proliferator-activated receptor alpha stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A, 112, 8445 - 8450. Corbett, G. T., Roy, A., and Pahan, K. (2012). Gemfibrozil, a Lipid-Lowering Drug, Upregulates IL-1 Receptor Antagonist in Mouse Cortical Neurons: Implications for Neuronal Self-Defense. J Immunol, 189, 1002 - 1013. Cotman, C.W. and Anderson, A.J. (1995) A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol, 10, 19 - 45. Dasgupta, S., Roy, A., Jana, M., Hartley, D.M. and Pahan, K. (2007) Gemfibrozil ameliorates relapsing - remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator - activated receptor - alpha. Mol Pharmacol, 72, 934 - 946. Datta, S.R., Brunet, A. and Greenberg, M.E. (1999) Cellular survival: a play in three Akts. Genes Dev, 13, 2905 - 2927. Datta, S.R., Ranger, A.M., Lin, M.Z., Sturgill, J.F., Ma, Y.C., Cowan, C.W., Dikkes, P., Korsmeyer, S.J. and Greenberg, M.E. (2002) Survival factor - mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell, 3, 631 - 643. De Duve, C. and Wattiaux, R. (1966) Functions of lysosomes. Annu Rev Physiol, 28, 435-492. Dhar, S., Bitting, R. L., Rylova, S. N., Jansen, P. J., Lockhart, E., Koeberl, D. D., Amalfitano, A. and Boustany, R. M. (2002) Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol, 51, 448-466. Ellert-Miklaszewska, A., Kaminska, B. and Konarska, L. (2005) Cannabinoids down-regulate PI3K / Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal, 17, 25-37. Geraets, R. D., Koh, S., Hastings, M. L., Kielian, T., Pearce, D. A. and Weimer, J. M. (2016) Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis. Orphanet J Rare Dis, 11, 40. Ghosh, A., Corbett, G. T., Gonzalez, F. J., and Pahan, K. (2012) Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor alpha: implications for late infantile Batten disease therapy. J Biol Chem, 287, 38922-38935. Ghosh, A., Jana, M., Modi, K., Gonzalez, F. J., Sims, K. B., Berry-Kravis, E., and Pahan, K. (2015) Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J Biol Chem, 290, 10309-10324. Ghosh, A., and Pahan, K. (2012a) Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J Biol Chem, 287, 27189-27203. Ghosh, A. and Pahan, K. (2012b) Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: Implications for neurodegenerative disorders. J Biol Chem. Ghosh, A., Roy, A., Liu, X. et al. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A, 104, 18754-18759. Ghosh, A., Roy, A., Matras, J., Brahmachari, S., Gendelman, H. E. and Pahan, K. (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci, 29, 13543-13556. Hachiya, Y., Hayashi, M., Kumada, S., Uchiyama, A., Tsuchiya, K. and Kurata, K. (2006) Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses. Acta Neuropathol, 111, 168-177. Jana, M., Jana, A., Liu, X., Ghosh, S. and Pahan, K. (2007) Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of Ikappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol, 179, 4142-4152. Jana, M. and Pahan, K. (2012) Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor beta. Neurochem Res, 37, 1718-1729. Khasnavis, S. and Pahan, K. (2014) Cinnamon treatment upregulates neuroprotective proteins Parkin and DJ-1 and protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neuroimmune Pharmacol, 9, 569-581. Kohan, R., Cismondi, I.A., Oller-Ramirez, A.M., Guelbert, N., Anzolini, T.V., Alonso, G., Mole, S.E., de Kremer, D.R. and de Halac, N.I. (2011) Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol, 12, 867-883. Koyasu, S. (2003) The role of PI3K in immune cells. Nat Immunol, 4, 313-319. Lane, S.C., Jolly, R.D., Schmechel, D.E., Alroy, J. and Boustany, R.M. (1996) Apoptosis as the mechanism of neurodegeneration in Batten's disease. J Neurochem, 67, 677 - 683. Li, Y., Tennekoon, G.I., Birnbaum, M., Marchionni, M.A. and Rutkowski, J.L. (2001) Neuregulin signaling through a PI3K / Akt / Bad pathway in Schwann cell survival. Mol Cell Neurosci, 17, 761 - 767. Macauley, S.L., Wong, A.M., Shyng, C. et al. (2014) An anti - neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS - directed gene therapy in murine infantile neuronal ceroid lipofuscinosis. J Neurosci, 34, 13077 - 13082. Otvos, J.D., Collins, D., Freedman, D.S., Shalaurova, I., Schaefer, E.J., McNamara, J.R., Bloomfield, H.E. and Robins, S.J. (2006) Low - density lipoprotein and high - density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High - Density Lipoprotein Intervention Trial. Circulation, 113, 1556 - 1563. Pahan, K. (2006) Lipid-lowering drugs. Cell Mol Life Sci, 63, 1165 - 1178. Pahan, K., Jana, M., Liu, X., Taylor, B. S., Wood, C. and Fischer, S. M. (2002) Gemfibrozil, a lipid lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem, 277, 45984 - 45991. Perez-Sala, D., Boya, P., Ramos, I., Herrera, M. and Stamatakis, K. (2009) The C-terminal sequence of RhoB directs protein degradation through an endo-lysosomal pathway. PLoS One, 4, e8117. Puranam, K., Qian, W. H., Nikbakht, K., Venable, M., Obeid, L., Hannun, Y. and Boustany, R. M. (1997) Upregulation of Bcl-2 and elevation of ceramide in Batten disease. Neuropediatrics, 28, 37 - 41. Robins, S. J., Collins, D., Wittes, J. T. et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA, 285, 1585 - 1591. Roy, A., Jana, M., Kundu, M., Corbett, G. T., Rangaswamy, S. B., Mishra, R. K., Luan, C. H., Gonzalez, F. J., and Pahan, K. (2015) HMG-CoA Reductase Inhibitors Bind to PPARalpha to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice. Cell Metab, 22, 253-265. Roy, A., Kundu, M., Jana, M., Mishra, R. K., Yung, Y., Luan, C. H., Gonzalez, F. J., and Pahan, K. (2016) Identification and characterization of PPARalpha ligands in the hippocampus. Nat Chem Biol, 12, 1075-1083. Roy, A., and Pahan, K. (2009) Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol, 31, 339-351. Rubins, H. B., and Robins, S. J. (1992) Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein-cholesterol concentrations. J Intern Med, 231, 421-426. Rubins, H.B., Robins, S.J., Collins, D. et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med, 341, 410-418. Saha, R.N. and Pahan, K. (2006) HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ, 13, 539-550. Shyng, C. and Sands, M.S. (2014) Astrocytosis in infantile neuronal ceroid lipofuscinosis: friend or foe? Biochem Soc Trans, 42, 1282-1285. Sleat, D.E., Donnelly, R.J., Lackland, H., Liu, C.G., Sohar, I., Pullarkat, R.K. and Lobel, P. (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science, 277, 1802-1805. Sleat, D.E., El-Banna, M., Sohar, I., Kim, K.H., Dobrenis, K., Walkley, S.U., and Lobel, P. (2008) Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late infantile neuronal ceroid lipofuscinosis. Mol Genet Metab, 94, 222 - 233. Sleat, D.E., Wiseman, J.A., El-Banna, M., et al. (2004) A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration. J Neurosci, 24, 9117 - 9126. Smalley, C.M., and Goldberg, S.J. (2008) A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol, 2, 106 - 111. Sohar, I., Sleat, D.E., Jadot, M., and Lobel, P. (1999) Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. J Neurochem, 73, 700 - 711. Superko, H.R., Berneis, K.K., Williams, P.T., Rizzo, M. and Wood, P.D. (2005) Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol, 96, 1266 - 1272. Walus, M., Kida, E. and Golabek, A.A. (2010) Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I. Hum Mutat, 31, 710 - 721.
Claims
1. Use of a composition for preparing a medicament for improving motor behavior of a subject with a neurodegenerative disease, wherein the composition comprises a therapeutically effective amount of an agent, which improves the motor behavior of a subject with the neurodegenerative disease relative to a control not receiving the agent; and the agent comprises a fibrate.
2. The use according to claim 1, wherein the fibrate is selected from the group consisting of gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate and clinofibrate.
3. The method according to claim 1, wherein the fibrate is gemfibrozil.
4. The use according to any one of claims 1 to 3, wherein the neurodegenerative disease is selected from the group consisting of neuronal ceroid lipofuscinosis, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, including Parkinson's plus diseases, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB).
5. The use according to any one of claims 1 to 4, wherein the neurodegenerative disease is late infantile neuronal ceroid lipofuscinosis.
6. Use of a composition for the preparation of a medicament for increasing the level of anti-inflammatory factors in the brain of a subject suffering from late infantile neuronal ceroid lipofuscinosis, wherein the composition comprises a composition of a therapeutically effective amount of a pharmaceutical agent, which increases the level of anti-inflammatory factors in the brain of the subject suffering from late infantile neuronal ceroid lipofuscinosis relative to a control not receiving the pharmaceutical agent; the pharmaceutical agent comprises a fibrate.
7. The use according to claim 6, wherein the fibrate is selected from the group consisting of gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate and clinofibrate.
8. The method according to claim 6, wherein the fibrate drug is gemfibrozil.
9. The use according to any one of claims 6 to 8, wherein the increase in the level of anti-inflammatory factors comprises an increase in the levels of suppressor of cytokine signaling 3 (SOCS3) and interleukin-1 receptor antagonist (IL-1Ra).
10. The use according to claims 1 and 6, wherein the medicament is for oral or parenteral administration.
